GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanoform Finland PLC (OSTO:NANOFS) » Definitions » ROE % Adjusted to Book Value

Nanoform Finland (OSTO:NANOFS) ROE % Adjusted to Book Value : -15.15% (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Nanoform Finland ROE % Adjusted to Book Value?

Nanoform Finland's ROE % for the quarter that ended in Dec. 2023 was -29.85%. Nanoform Finland's PB Ratio for the quarter that ended in Dec. 2023 was 1.97. Nanoform Finland's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was -15.15%.


Nanoform Finland ROE % Adjusted to Book Value Historical Data

The historical data trend for Nanoform Finland's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanoform Finland ROE % Adjusted to Book Value Chart

Nanoform Finland Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial - -7.38 -4.71 -8.80 -13.80

Nanoform Finland Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.27 -14.05 -16.58 -11.22 -15.15

Competitive Comparison of Nanoform Finland's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Nanoform Finland's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nanoform Finland's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nanoform Finland's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Nanoform Finland's ROE % Adjusted to Book Value falls into.



Nanoform Finland ROE % Adjusted to Book Value Calculation

Nanoform Finland's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-27.19% / 1.97
=-13.80%

Nanoform Finland's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-29.85% / 1.97
=-15.15%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nanoform Finland ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Nanoform Finland's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Nanoform Finland (OSTO:NANOFS) Business Description

Traded in Other Exchanges
Address
Cultivator II, Viikinkaari 4, Helsinki, FIN, 00790
Nanoform Finland PLC is a nanoparticle medicine-enabling company. The company works together with pharma and biotech partners to reduce attrition in clinical trials and enhance their molecules' formulation performance through its nano-forming services. Its patented and scalable Controlled Expansion of Supercritical Solutions (CESS) technology produces nano-formed API particles as small as 10nm. This enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and by improving their bioavailability. Its technology provides novel opportunities in many value-enhancing drug delivery applications.

Nanoform Finland (OSTO:NANOFS) Headlines

No Headlines